Remedium Lifecare Q2 Results Out, Announces Fund Raising & Key Acquisitions

Since the penny stock has released its financial results for the quarter that ended on September 30, 2024, Remedium Lifecare shares are anticipated to be the focus of attention in the next sessions. Remedium Lifecare's net profit decreased 72.74% to Rs 1.78 crore in the September 2024 quarter from Rs 6.53 crore in the September 2023 quarter. In comparison to the year-ago quarter, which ended in September 2023, when sales were Rs 468.57 crore, they fell 94.65% to Rs 25.08 crore in the quarter that concluded in September 2024.

Remedium Lifecare Ltd has also established a fully owned subsidiary firm REMLIFE GLOBAL PTE LTD, located in Singapore, which is in line with its rapid growth policy. The new subsidiary's Corporate Entity Number is 202439223M as registered with the Accounting and Corporate Regulatory Authority. This strategy is aimed at supporting the business's intention to acquire a major project overseas estimated at approximately USD 200 million. Remedium Lifecare Limited has entered into alliances with Wave Capital Limited, rendering unto them the right of exclusive appointment as the Lead Manager of the Project. Wave Capital will operate as a Lead Arranger where its objectives would be to engage in high-end businesses dealing with USD 100 million net worth or enterprise-worth businesses. The agreement, which is for a year, is expected to create opportunities for Remedium in strategic international business landscapes.

Moreover, the Board of Directors of the company had previously approved a plan to increase capital injection amounting to USD 25 million. These funds will be raised through various instruments including Foreign Currency Convertible Bonds FCCB, private placement, rights issue, preferential issue, Follow-up Public Offer FPO, Qualified Institutional Placement QIP, Global Depository Receipts and American Depository Receipts. This action has to be confirmed at the meeting of shareholders and the conclusion of regulators.

Both Remedium and Alpha Chem as two overseas firms are together in the robust growth of the electric vehicle (EV) industry. Remedium has joined Angel Partners Ltd. for the purpose of acquiring advanced lithium carbonate production technology. In this regard, Remedium entered into a supply agreement with Alfa Chemicals and Solvents Ltd. for the purchase of technical lithium carbonate for the period of 20-25 million dollars in 2025. Such a move gives Remedium an opportunity to service the growing market of lithium-ion batteries for e vehicles and portable electronics and enables it to source lithium carbonate in India through contract manufacturing agreements.

In terms of the company's performance, it has continued to perform impressively well. For Q1FY25, Remedium Lifecare Ltd declared net sales of Rs 77.70 crore along with a net profit of Rs 1.64 crore. In respect of FY24, the company reported total income amounting to Rs 4,062.80 crore, an increase of 698 per cent from FY23, and a net profit of Rs 32.72 crore, an increase of 504 percent from the previous year. The company's market capitalization is over Rs 280 crore and its stock price has also increased in value at a 100% CAGR over the last three years.

Remedium Lifecare Ltd started its operations in 1988 and has become one of the main companies in the pharmaceutical value chain as it's been importing and selling active pharmaceutical ingredients along with intermediate chemicals to innovative and generic drug manufacturers all over the world. This company supplies api's for the production of cholesterol reducers, antidepressants, asthma and allergy medicines.